KR102290803B1 - 뉴로텐신 수용체 리간드 - Google Patents

뉴로텐신 수용체 리간드 Download PDF

Info

Publication number
KR102290803B1
KR102290803B1 KR1020157018171A KR20157018171A KR102290803B1 KR 102290803 B1 KR102290803 B1 KR 102290803B1 KR 1020157018171 A KR1020157018171 A KR 1020157018171A KR 20157018171 A KR20157018171 A KR 20157018171A KR 102290803 B1 KR102290803 B1 KR 102290803B1
Authority
KR
South Korea
Prior art keywords
compound
formula
group
acceptor
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157018171A
Other languages
English (en)
Korean (ko)
Other versions
KR20150092300A (ko
Inventor
프랭크 오스터캠프
크리스티안 스멀링
울리치 라이네케
크리스티안 하세
얀 운게비쓰
Original Assignee
쓰리비 파마슈티컬스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쓰리비 파마슈티컬스 게엠베하 filed Critical 쓰리비 파마슈티컬스 게엠베하
Publication of KR20150092300A publication Critical patent/KR20150092300A/ko
Application granted granted Critical
Publication of KR102290803B1 publication Critical patent/KR102290803B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020157018171A 2012-12-07 2013-12-06 뉴로텐신 수용체 리간드 Active KR102290803B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12008208.6 2012-12-07
EP12008208.6A EP2740726A1 (en) 2012-12-07 2012-12-07 Neurotensin receptor ligands
PCT/EP2013/003700 WO2014086499A1 (en) 2012-12-07 2013-12-06 Neurotensin receptor ligands

Publications (2)

Publication Number Publication Date
KR20150092300A KR20150092300A (ko) 2015-08-12
KR102290803B1 true KR102290803B1 (ko) 2021-08-18

Family

ID=47355771

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157018171A Active KR102290803B1 (ko) 2012-12-07 2013-12-06 뉴로텐신 수용체 리간드

Country Status (20)

Country Link
US (2) US10961199B2 (enExample)
EP (3) EP2740726A1 (enExample)
JP (2) JP6576828B2 (enExample)
KR (1) KR102290803B1 (enExample)
CN (2) CN109320502B (enExample)
AU (1) AU2013354422B2 (enExample)
BR (1) BR112015012530B1 (enExample)
CA (1) CA2893605C (enExample)
DK (2) DK2928870T3 (enExample)
ES (2) ES2795923T3 (enExample)
FI (1) FI3712131T3 (enExample)
HU (2) HUE061839T2 (enExample)
IL (1) IL239080B (enExample)
MX (1) MX370354B (enExample)
PL (2) PL2928870T3 (enExample)
PT (2) PT2928870T (enExample)
RU (1) RU2671970C2 (enExample)
SG (2) SG10201704564QA (enExample)
WO (1) WO2014086499A1 (enExample)
ZA (1) ZA201503446B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2954934A1 (en) * 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
CA2949936C (en) * 2014-06-10 2022-10-18 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954933A1 (en) * 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
US11034727B2 (en) 2015-11-24 2021-06-15 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
BR112019011186A2 (pt) 2016-12-01 2019-10-08 Regeneron Pharmaceuticals, Inc. conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
CN110650974B (zh) 2017-02-10 2024-04-19 瑞泽恩制药公司 用于免疫-pet成像的放射性标记的抗-lag3抗体
JP7304846B2 (ja) 2017-07-24 2023-07-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｃｄ８抗体およびその使用
SI3997103T1 (sl) 2019-07-08 2025-04-30 3B Pharmaceuticals Gmbh Spojine, ki obsegajo ligand proteina za aktiviranje fibroblastov in uporaba le teh
CN111875667B (zh) * 2020-07-16 2021-12-21 南方科技大学 有机金属螯合物及其制备方法与应用、探针
MX2023004715A (es) * 2020-10-22 2023-05-10 Nihon Mediphysics Co Ltd Metodo para producir un complejo de circonio radioactivo.
AR125403A1 (es) * 2021-04-23 2023-07-12 Fusion Pharmaceuticals Inc Métodos para el tratamiento de cánceres
WO2022241470A1 (en) * 2021-05-13 2022-11-17 The General Hospital Corporation Molecular probes for in vivo detection of aldehydes
WO2022261771A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel
WO2022261770A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and folfirinox
WO2022266357A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and napox
WO2023141722A1 (en) * 2022-01-28 2023-08-03 Fusion Pharmaceuticals Inc. Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy
JP2025506705A (ja) * 2022-02-18 2025-03-13 フル－ライフ・テクノロジーズ・ホンコン・リミテッド ニューロテンシン受容体を標的とする化合物および放射性リガンドおよびその使用
EP4518912A1 (en) * 2022-05-03 2025-03-12 The University of North Carolina at Chapel Hill Development of ntsr targeted agents for imaging and therapy applications
US12091454B2 (en) 2022-12-28 2024-09-17 Development Center For Biotechnology Humanized anti-human neurotensin receptor 1 antibodies and their uses
US20250213735A1 (en) * 2023-12-28 2025-07-03 Radionetics Oncology, Inc. Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof
WO2025146126A1 (en) * 2024-01-04 2025-07-10 Full-Life Technologies Hk Limited Preparation method of compounds targeting neurotensin receptor

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110321A (en) 1976-07-12 1978-08-29 Folkers Karl Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity
US4425269A (en) 1982-06-07 1984-01-10 Merck & Co., Inc. Metabolically protected analogs of neurotensin
US4439359A (en) 1982-07-02 1984-03-27 Merck & Co., Inc. Cyclic octapeptide analogs of neurotensin
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
CA2086453A1 (en) 1992-12-30 1994-07-01 Mcgill University Marker for neurotensin receptor
US5407916A (en) 1993-02-16 1995-04-18 Warner-Lambert Company Neurotensin mimetics as central nervous system agents
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
EP0752873A4 (en) 1994-02-18 2002-05-15 Mallinckrodt Inc MARKED PEPTIDE COMPOUNDS
EP0820466A2 (en) 1995-04-04 1998-01-28 Advanced Bioconcept Inc. Fluorescent peptides
US6054557A (en) 1995-04-04 2000-04-25 Advanced Bioconcept (1994) Ltd. Fluorescent peptides
FR2732967B1 (fr) 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
AU6352296A (en) 1995-07-20 1997-02-18 Advanced Bioconcept, Inc. Cell sorting with fluorescent peptides
JP2001511152A (ja) 1997-02-03 2001-08-07 マリンクロッド・インコーポレイテッド 悪性ヒト腫瘍の検出および位置特定法
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US6214790B1 (en) 1998-04-10 2001-04-10 Mayo Foundation For Medical Education And Research Neo-tryptophan
EP1194444A2 (en) 1999-06-24 2002-04-10 BioSynthema Inc. Labeled neurotensin derivatives with improved resistance to enzymatic degradation
AU2004264857B2 (en) * 2003-07-09 2010-06-10 Sutter West Bay Hospitals Remote detection of substance delivery to cells
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
JP2010516679A (ja) * 2007-01-19 2010-05-20 マリンクロット インコーポレイテッド 診断用および治療用シクロオキシゲナーゼ−２結合リガンド
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
EP2334642B1 (en) * 2008-09-16 2014-01-01 The Regents Of The University Of California Simplified one-pot synthesis of [18f]sfb for radiolabeling
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
EP2374003B1 (en) * 2009-01-07 2015-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment, the prognostic assessment and the detection of breast cancer
EP2454272B1 (en) 2009-07-16 2017-08-23 IASON GmbH Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
WO2011156557A2 (en) * 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor

Also Published As

Publication number Publication date
KR20150092300A (ko) 2015-08-12
DK3712131T3 (da) 2023-03-20
FI3712131T3 (fi) 2023-03-28
PL3712131T3 (pl) 2023-05-02
JP2019218375A (ja) 2019-12-26
JP2016501238A (ja) 2016-01-18
JP7042776B2 (ja) 2022-03-28
SG10201704564QA (en) 2017-07-28
ES2795923T3 (es) 2020-11-25
MX370354B (es) 2019-12-10
ES2941629T3 (es) 2023-05-24
EP3712131A1 (en) 2020-09-23
PL2928870T3 (pl) 2020-09-21
EP2740726A1 (en) 2014-06-11
IL239080A0 (en) 2015-07-30
ZA201503446B (en) 2016-01-27
WO2014086499A8 (en) 2014-12-31
US20150299133A1 (en) 2015-10-22
HUE061839T2 (hu) 2023-08-28
PT2928870T (pt) 2020-05-29
SG11201503880YA (en) 2015-06-29
US10961199B2 (en) 2021-03-30
CN104837819A (zh) 2015-08-12
EP2928870A1 (en) 2015-10-14
EP2928870B1 (en) 2020-04-08
HUE050388T2 (hu) 2020-11-30
BR112015012530B1 (pt) 2022-07-19
AU2013354422A1 (en) 2015-05-28
CA2893605A1 (en) 2014-06-12
MX2015007193A (es) 2016-03-17
EP3712131B1 (en) 2023-02-01
DK2928870T3 (da) 2020-07-13
CN104837819B9 (zh) 2019-07-09
CN109320502B (zh) 2022-06-07
BR112015012530A2 (pt) 2017-09-12
CA2893605C (en) 2021-08-10
RU2671970C2 (ru) 2018-11-08
HK1210148A1 (en) 2016-04-15
CN109320502A (zh) 2019-02-12
WO2014086499A1 (en) 2014-06-12
JP6576828B2 (ja) 2019-09-18
RU2015127086A (ru) 2017-01-11
AU2013354422B2 (en) 2018-03-15
IL239080B (en) 2019-06-30
CN104837819B (zh) 2018-12-07
PT3712131T (pt) 2023-04-04
US20210087149A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
KR102290803B1 (ko) 뉴로텐신 수용체 리간드
Grob et al. Design of radiolabeled analogs of minigastrin by multiple amide-to-triazole substitutions
KR20250016195A (ko) 전립선-특이적 막 항원(psma) 리간드
HK40037865B (en) Neurotensin receptor ligands
HK40037865A (en) Neurotensin receptor ligands
HK40003630A (en) Neurotensin receptor ligands
HK40003630B (en) Neurotensin receptor ligands
US20250303005A1 (en) Prostate specific membrane antigen (psma) ligands with improved renal clearance
HK1210148B (en) Neurotensin receptor ligands
CN121013861A (zh) 具有生物分布调节剂的抑胃肽受体配体
KR20250175337A (ko) 생체분포 변형제를 갖는 위 억제 펩티드 수용체 리간드
CN118632858A (zh) 抑胃肽受体配体
Mascarin Triazole-based Radiopeptidomimetics: Novel Neurotensin (8-13) Analogues with Increased Metabolic Stability

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5